COVID-19 has changed our society – people are suffering, world economies have turned upside down and our life as we know it has changed forever. The treatment for COVID-19, when found, will bring a lot of value to society – but what price are we prepared to pay for this value? How do we make sure innovation in medicine continues to grow after this pandemic is over? And what incentives should society offer for current and future work in keeping us safe?
Join us on Tuesday, July 14 from 3:30 pm – 5 pm ET for a lively discussion with experts who have recently written articles addressing these questions:
- Peter B. Bach, MD, MAPP, Director, Center for Health Policy and Outcomes, Memorial Sloan Kettering Cancer Center
- Robert W. Dubois, MD, PhD, Chief Science Officer, National Pharmaceutical Council
- Sarah K. Emond, MPP, Executive Vice President and Chief Operating Officer, Institute for Clinical and Economic Review
- Craig Garthwaite, PhD, MPP, Herman R. Smith Research Professor in Hospital and Health Services, an Associate Professor of Strategy, and the Director of the Program on Healthcare, Kellogg School of Management, Northwestern University
- Peter K. Neumann, ScD, Director, Center for the Evaluation of Value and Risk in Health at the Institute for Clinical Research and Health Policy Studies at Tufts Medical Center; Professor of Medicine, Tufts University School of Medicine